NCT05354973

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy: Feasibility Study (CARTePRO)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 11 (estimated)
• Sponsor: Stiftung Swiss Tumor Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assessments will be explored for their feasibility to engage in monitoring and management of CAR T-related toxicities as well as using these digital ePRO tools may improve both, its safety and accessibility.

Conditions

• Patient Reported Outcome Measures
• CAR T-Cell Therapy

Interventions

Type	Name	Description
DEVICE	Consilium CareTM	This is an observational study using the Consilium CareTM smartphone ePRO application.

Timeline

• Start date: 2022-03-21
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2022-05-02
• Last updated: 2024-04-19

Locations

1 site across 1 country: Switzerland